查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
體外診斷進行數量：2024-2029
市場調查報告書
商品編碼
1550800

體外診斷進行數量：2024-2029

IVD Test Procedure Volumes, 2024-2029
出版日期: | 出版商: Kalorama Information | 英文 405 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

體外診斷（IVD）市場作為一個快速發展的市場，在新技術、不斷變化的醫療保健支出以及快速成長的精準診斷需求的推動下，在2024年實現成長。

本報告調查了體外診斷的數量，並依類型、地區和國家分析了2024年至2029年的趨勢。涵蓋從自我檢測到專業護理點（POC）、臨床化學和血液學。

目次

第1章 執行摘要

第2章 簡介

  • 概要
  • 業界動向
  • 新冠肺炎（COVID-19）
  • 人口動向
  • 世界人口與老化
  • 人員削減
  • 慢性疾病增加
  • 個人化醫療服務
  • 新傳染病的威脅
  • 壁蝨媒傳疾病（TBD）
  • 茲卡熱
  • 恰加斯
  • 登革熱
  • 伊波拉病毒
  • 屈公病
  • 中東呼吸道症候群冠狀病毒（MERS-CoV）
  • 馬堡病毒
  • SARS-CoV-2（COVID-19）
  • 猴痘
  • 新興國家與市場

第3章 IVD檢驗環節

  • IVD 測試的趨勢
  • 細分市場成長預測
  • POC 測試
  • 臨床化學
  • 免疫測定
  • 質量分析（免疫）
  • 分子檢測
  • 血液學
  • 凝固
  • 傳統微生物學
  • 血液型
  • 組織學/細胞學
  • 細分產品銷售

第4章 世界IVD市場

  • 一般
  • 北美
  • 米國
  • 加拿大
  • 墨西哥、中美洲和南美洲
  • 巴西
  • 墨西哥
  • 其他中美洲和南美洲
  • 西歐
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 其他西歐
  • 東欧
  • 俄羅斯
  • 其他東歐
  • 亞太地區
  • 中國
  • 日本
  • 其他亞洲國家和地區
  • 中東
  • 土耳其
  • 其他中東地區
  • 非洲

第5章 護理點（POC）技術

  • 全球 POC 測試數量（依測試類型）
  • POC 自測試
  • 傳統血糖監測活動
  • 持續血糖監測
  • 懷孕和生育力檢測
  • 凝血試驗
  • 糞便潛血試驗
  • 濫用藥物測試
  • 幽門螺旋桿菌檢測
  • 愛滋病毒檢測
  • 感染症
  • 膽固醇測試
  • POC檢定
  • 價格趨勢

第6章 臨床化學檢測技術

  • 檢查類型
  • 一般化學
  • 血氣和電解質
  • 尿液測試
  • 臨床化學產品的全球銷售
  • 價格趨勢

第7章 免疫測定技術

  • 技術
  • 標籤技術
  • 酵素免疫測定法
  • 螢光偏光免疫分析（FPIA）
  • 放射免疫測定法（RIA）
  • 測試技術與產品銷售
  • 心臟標記
  • 腫瘤標記
  • 自體免疫疾病
  • 過敏症狀
  • 甲狀腺疾病
  • 蛋白質
  • 貧血
  • 不孕症測試
  • 治療藥物監測
  • 維生素D
  • 糖尿病/HbA1c
  • 濫用藥物
  • 感染症
  • 機器
  • 價格趨勢

第8章 分子測試技術

  • 檢查類型
  • 測試技術
  • 感染症
  • 驗血
  • 癌症
  • 移植匹配
  • 血栓形成性SNP
  • 遺傳性疾病
  • 其他分子測試
  • 出生前
  • 分子 IVD 產品的全球銷售
  • 價格趨勢

第9章 實驗室驗血程序

  • 檢查類型
  • 血液學產品的全球銷售
  • 價格趨勢

第10章 凝血檢驗技術

  • 檢查類型
  • 混凝劑的全球銷售
  • 價格趨勢

第11章 微生物學檢測技術

  • 檢查類型
  • ID/AST 自動化面板和試劑
  • 手動面板和試劑
  • 血液培養
  • 顯色培養基
  • 迅速微生物學的検査
  • 質量分析
  • 傳統 IVD 微生物學產品的全球銷售
  • ID/AST 組合與試劑
  • 血液培養
  • 顯色培養基
  • 迅速微生物學的検査
  • 質量分析
  • 價格趨勢

第12章 血型判定程序

  • 檢查類型
  • 血型測定產品銷售
  • 價格趨勢

第13章 組織學/細胞學檢測技術

  • 檢查類型
  • 免疫組織化學
  • 原位雜交測試
  • 巴氏試驗
  • 傳統非巴氏染色
  • 循環腫瘍細胞
  • 流式細胞儀
  • 組織學/細胞學 IVD 產品銷售
  • 價格趨勢

第14章 公司簡介

  • Abbott Diagnostics
  • Core Lab
  • i-STAT Business
  • Becton, Dickinson and Company (BD)
  • bioMerieux Inc.
  • BioFire Diagnostics Business
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Dexcom
  • DiaSorin
  • Exact Sciences
  • Hologic, Inc.
  • PANTHER Molecular System
  • Illumina
  • Natera
  • QuidelOrtho Corporation
  • The Solana Business
  • Revvity
  • Roche Diagnostics
  • Core Lab
  • Core Molecular
  • cobas Liat System
  • HPV
  • 血液銀行
  • 移植醫學
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc
  • Werfen

聯絡我們

簡介目錄
Product Code: 24-025

Act Now - Be Prepared for Tomorrow's IVD Market

Don't miss your chance to leverage Kalorama Information's expert insights. Equip your business with the knowledge to anticipate changes, optimize product development, and maximize your strategies in the dynamic IVD landscape.

Ready to take action? Purchase the "IVD Test Procedure Volumes, 2024-2029" report today and secure your competitive advantage in this billion-dollar industry.

Kalorama Information's "IVD Test Procedure Volumes, 2024-2029" report provides a deep dive into the global trends shaping in vitro diagnostic (IVD) procedural volumes. Designed to complement Kalorama's comprehensive market analysis in The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this essential report delivers actionable data on the growth, challenges, and emerging opportunities in the IVD space.

As a rapidly evolving market, the IVD landscape in 2024 is set to thrive, driven by new technologies, evolving healthcare spending, and a surge in demand for precision diagnostics. Our report not only identifies the most significant procedural segments but also breaks down the impact of ongoing innovations.

With this detailed market research, you can stay ahead of industry developments and make informed business decisions. Whether you are looking to expand your product portfolio, explore new market segments, or refine your strategic approach, "IVD Test Procedure Volumes, 2024-2029" offers the data and insights you need to succeed.

Why Choose This Report?

  • Comprehensive Market Data
    • Gain an in-depth understanding of IVD procedural volumes by type, region, and country. From self-testing and professional point-of-care (POC) to clinical chemistry, hematology, and beyond-this report covers it all.
  • Unmatched Insights into Growth Opportunities
    • Identify high-growth segments by exploring emerging markets and the potential of precision medicine applications.
  • Forward-Looking Analysis
    • Understand the trends impacting the IVD market, including shifts in regulatory landscapes, new product developments, and changing disease profiles. This report provides a comprehensive forecast from 2024 to 2029.
  • Strategic Guidance for Industry Players
    • Discover how market dynamics, healthcare system trends, and cost pressures are shaping the future of IVD. Use these insights to develop strategies for product positioning, market entry, and growth.

Scope & Methodology

The report includes:

  • Global IVD Procedure Volumes by type, covering self and professional POC, clinical chemistry, immunoassay, molecular diagnostics, hematology, coagulation, microbiology, blood banking, and histology/cytology.
  • Regional and Country-Specific Data for IVD procedures and their projected growth rates.
  • Cost Analysis of various IVD tests to evaluate profitability and potential revenue streams.

Table of Contents

Chapter One: Executive Summary

  • IVD Procedure Volume Estimate and Forecast
    • Figure 1-1: Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)
  • Scope & Methodology
  • About Kalorama Information

Chapter Two: Introduction

  • Overview
  • Industry Trends
    • Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
    • Figure 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
  • COVID-19
  • Demographic Trends
  • Global Population and Aging
    • Figure 2-2: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
    • Figure 2-3: Global Population Distribution, 2022
    • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
  • Workforce Reduction
    • Table 2-3: Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)
  • Increase in Chronic Diseases
    • Figure 2-4: Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)
  • Personalized Medicine
  • New Infectious Disease Threats
    • Table 2-4: Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats
  • Tickborne Diseases (TBDs)
  • Zika
  • Chagas
  • Dengue
  • Ebola
  • Chikungunya
  • Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
  • Marburg
  • SARS-CoV-2 (COVID-19)
  • Monkeypox
    • Table 2-5: Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox
  • Emerging and Emerged Markets
    • Table 2-6: Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)

Chapter Three: IVD Testing Segments

  • IVD Testing Trends
    • Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-2: IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-3: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-4: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-5: IVD Procedural Volume excluding Blood Glucose Tests, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-6: IVD Procedural Volume excluding Blood Glucose Tests, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-7: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-8: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Segment Growth Projections
  • POC Testing
    • Table 3-5: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
    • Figure 3-9: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
  • Clinical Chemistry
    • Table 3-6: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-10: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Immunoassays
    • Table 3-7: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-11: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Mass Spectrometry (Immuno)
    • Table 3-8: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-12: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Molecular Assays
    • Table 3-9: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-13: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Hematology
    • Table 3-10: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-14: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Coagulation
    • Table 3-11: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-15: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Conventional Microbiology
    • Table 3-12: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-16: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Blood Grouping/Typing
    • Table 3-13: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-17: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Histology/Cytology
    • Table 3-14: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Figure 3-18: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Segment Product Sales
    • Table 3-15: IVD Product Sales including Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-19: IVD Product Sales including Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-20: IVD Product Sales including Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-16: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-21: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-22: IVD Product Sales including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-17: IVD Product Sales excluding Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-23: IVD Product Sales excluding Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-24: IVD Product Sales excluding Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Table 3-18: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-25: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Figure 3-26: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)

Chapter Four: Global IVD Markets

  • General
    • Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, & South America; Middle East; North America [United States; Canada]; Western Europe)
    • Figure 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
    • Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
    • Figure 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
  • North America
    • Table 4-3: North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
    • Figure 4-3: North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)
  • United States
  • Canada
  • Mexico, Central & South America
    • Table 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
    • Figure 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Brazil
  • Mexico
  • Other Central & South America
    • Argentina
    • Chile
    • Colombia
    • Peru
    • Venezuela
    • All Other Countries & Territories
  • Western Europe
    • Table 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Other Western Europe
    • Austria
    • Belgium
    • Denmark
    • Finland
    • Greece
    • Ireland
    • Norway
    • Netherlands
    • Portugal
    • Sweden
    • Switzerland
    • All Other Countries & Territories
  • Eastern Europe
    • Table 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Russia
  • Other Eastern Europe
    • Czech Republic
    • Hungary
    • Poland
    • Romania
    • Ukraine
    • All Other Countries
  • Asia/Pacific
    • Table 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
    • Figure 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • China
  • Japan
  • Other Asian Countries and Territories
    • Australia
    • Hong Kong
    • India
    • Indonesia
    • Malaysia
    • Pakistan
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
    • New Zealand
    • All Other Countries & Territories
  • Middle East
    • Table 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Turkey
  • Other Middle East
    • Iran
    • Iraq
    • Israel
    • Saudi Arabia
    • United Arab Emirates
    • All Other Countries
  • Africa
    • Table 4-9: Africa IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
    • Figure 4-9: Africa IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
    • Nigeria
    • South Africa
    • All Other Countries & Territories

Chapter Five: Point-of-Care (POC) Procedures

  • Global POC Procedure Volume by Test Type
    • Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2024-2029
    • Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2024-2029
    • Figure 5-1: Regional POC Procedure Volumes excluding blood glucose tests, 2024 (Europe, Japan, United States, Rest of World)
  • POC Self Tests
    • Table 5-3: POC Self-Test Procedural Volume, by Type, 2024-2029 (millions) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
  • Traditional Blood Glucose Monitoring Activities
  • Continuous Blood Glucose Monitoring
  • Pregnancy and Fertility Testing
  • Coagulation Testing
  • Fecal Occult Blood Testing
  • Drugs of Abuse Testing
  • 1. Pylori Testing
  • HIV Testing
  • Infectious Disease
  • Cholesterol Testing
  • POC Urinalysis Testing
  • Other POC Self-Testing
  • POC Self-Testing Product Sales
    • Table 5-4: POC Self-Test Product Sales, by Type, 2024-2029 ($ million) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
  • Pricing Trends
    • Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2024-2029 (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
  • POC Professional Testing
    • Table 5-6: POC Professional Procedural Volume, by Type, 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
  • POC Professional Blood Glucose Testing Procedures
  • POC Professional Critical Care Testing
  • POC Fertility Testing
  • POC Professional Infectious Disease Testing
  • POC Professional Cardiac Marker Testing
  • POC Professional Cholesterol/Lipid Testing
  • POC Professional Coagulation Testing
  • POC Professional HbA1C Testing
  • POC Professional Hematology Testing
  • POC Professional Fecal Occult Blood Screening
  • POC Professional Drugs of Abuse Testing
  • POC Professional Urinalysis Testing
  • Other POC Professional Testing
  • POC IVD Product Sales
    • Table 5-7: POC Professional IVD Product Sales, by Type, 2024-2029 ($ million) (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
  • Pricing Trends
    • Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)

Chapter Six: Clinical Chemistry Procedures

  • Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2024-2029 (Blood Gas Analysis, General Chemistry, Urinalysis)
  • Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
  • Types of Tests
  • General Chemistry
    • Enzymes
    • Glucose
    • Lipids
    • Proteins
    • Other Compounds
  • Blood Gases & Electrolytes
  • Urinalysis
  • Global Sales of Clinical Chemistry Products
    • Table 6-2: Clinical Chemistry Product Sales, by Type, 2024-2029 ($ million) (Blood Gas Analysis; General Chemistry; Urinalysis)
  • Pricing Trends
    • Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2024-2029 (Blood Gas Analysis; General Chemistry; Urinalysis)

Chapter Seven: Immunoassay Procedures

  • Technologies
  • Labeling Techniques
  • Enzyme Immunoassays
  • Fluorescence Polarization Immunoassays (FPIAs)
  • Radioimmunoassays (RIAs)
    • Table 7-1: Immunoassay Procedural Volume, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
    • Figure 7-1: Regional Immunoassay Procedure Volumes, 2024
  • Testing Procedures & Product Sales
    • Table 7-2: Immunoassay Product Sales, by Type, 2024-2029 ($ million) (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
  • Cardiac Markers
  • Tumor Markers
  • Autoimmune Conditions
  • Allergy Conditions
  • Thyroid Conditions
  • Proteins
    • Alzheimer's Disease
  • Anemia
  • Fertility Testing
  • Therapeutic Drug Monitoring
  • Vitamin D
  • Diabetes/HbA1c
  • Drugs of Abuse
  • Infectious Diseases
    • Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2024-2029 (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
    • Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
  • Instruments
  • Pricing Trends
    • Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)

Chapter Eight: Molecular Testing Procedures

  • Table 8-1: Molecular Assay Procedural Volume, by Type, 2024-2029 (millions) (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
  • Figure 8-1: Regional Molecular Assay Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
  • Types of Tests
  • Testing Technologies
  • Infectious Diseases
    • Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2024-2029 (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
  • Blood Screening
  • Cancer
  • Transplant Matching
  • Thrombophilia SNPs
  • Inherited Diseases
  • Other Molecular Tests
  • Prenatal
  • Global Sales of Molecular IVD Products
    • Table 8-3: Molecular Assay Product Sales, by Type, 2024-2029 ($ million) (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
    • Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
  • Pricing Trends
    • Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2024-2029 (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)

Chapter Nine: Laboratory-Based Hematology Procedures

  • Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2024-2029 (Complete Blood Count; Other Hematology Tests)
  • Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
  • Types of Tests
  • Global Sales of Hematology Products
    • Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2024-2029 ($ million) (Complete Blood Count; Other Hematology Tests)
  • Pricing Trends
    • Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2024-2029 (Complete Blood Count, Other Hematology Tests)

Chapter Ten: Coagulation Testing Procedures

  • Table 10-1: Coagulation Procedural Volume, 2024-2029 (D-dimer, PT/INR)
  • Figure 10-1: US/ROW Coagulation Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • Global Sales of Coagulation Products
    • Table 10-2: Coagulation Product Sales, 2024-2029 ($ million) (D-dimer, PT/INR)
  • Pricing Trends
    • Table 10-3: Coagulation $ Products per Procedure, 2024-2029 (D-dimer, PT/INR)

Chapter Eleven: Microbiology Procedures

  • Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
  • Figure 11-1: Regional Microbiology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • ID/AST Automated Panels & Reagents
  • Manual Panels & Reagents
  • Blood Culture
  • Chromogenic Media
  • Rapid Microbiological Tests
  • Mass Spectrometry
  • Global Sales of Conventional IVD Microbiology Products
  • ID/AST Panels & Reagents
  • Blood Culture
  • Chromogenic Media
  • Rapid Microbiological Tests
  • Mass Spectrometry
    • Table 11-2: Conventional Microbiology Product Sales, by Type, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
  • Pricing Trends
    • Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2024-2029
    • (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)

Chapter Twelve: Blood Grouping/Typing Procedures

  • Table 12-1: Blood Grouping/Typing Procedure Volumes, 2024-2029
  • Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • Blood Grouping/Typing Product Sales
    • Table 12-2: Blood Grouping/Typing Product Sales, 2024-2029 ($ million)
  • Pricing Trends
    • Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2024-2029

Chapter Thirteen: Histology/Cytology Procedures

  • Table 13-1: Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
  • Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
  • Types of Tests
  • Immunohistochemistry Tests
  • In Situ Hybridization Tests
  • Pap Tests
  • Traditional Non-Pap Stains
  • Circulating Tumor Cells
  • Flow Cytometry
  • Histology/Cytology IVD Product Sales
    • Table 13-2: Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
  • Pricing Trends
    • Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029

Chapter Fourteen: Company Profiles

  • Table 14-1: Revenues of Selected Top 20 IVD Companies, 2023 and estimated 2024 ($ million) (Abbott Diagnostics; Agilent; Becton Dickinson; bioMerieux; Bio-Rad Laboratories; Bruker - CALID; Danaher; Dexcom; DiaSorin; Exact Sciences; Hologic; Illumina; Natera; QuidelOrtho; Revvity; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Thermo Fisher Scientific; Werfen)
  • Abbott Diagnostics
  • Recent Revenue History
    • Table 14-2: Abbott Diagnostic Revenues, 2017-2023 (million $)
  • Core Lab
  • Hematology
  • Blood Banking
  • Infectious Diseases - Molecular
  • Diabetes
  • HIV Point of Care
  • i-STAT Business
  • COVID-19
  • Agilent Technologies
  • Recent Revenue History
    • Table 14-3: Agilent Revenues, 2017-2023 (million $)
  • Agilent in Genomics
  • Cytogenetic Analysis
  • Sequencing
  • Flow Cytometry
  • Companion Diagnostics - Dako
  • COVID-19
  • Becton, Dickinson and Company (BD)
  • Recent Revenue History
    • Table 14-4: BD Diagnostic Revenues, 2017-2023 (million $) FYE Sept 30
  • Cytology
  • Molecular Microbiology
  • Traditional Microbiology - ID/AST
  • Blood Culture
  • Hospital Acquired Infections
  • Blood Collection
  • Mass Spectrometry
  • COVID-19
  • bioMerieux Inc.
  • Recent Revenue History
    • Table 14-5: bioMerieux IVD Revenues, 2017-2023 (million $)
  • Traditional Microbiology
  • Blood Culture
  • Immunoassays
  • Mass Spectrometry
  • BioFire Diagnostics Business
  • COVID-19
  • Bio-Rad Laboratories, Inc.
  • Recent Revenue History
    • Table 14-6: Bio-Rad Diagnostics Revenues, 2017-2023 (million $)
  • Blood Bank
  • Immunoassays
  • COVID-19
  • Bruker Corporation
  • Recent Revenue History
    • Table 14-7: Bruker Revenue History Product Revenue, 2017-2023 ($ million)
  • Acquisitions and Collaborations
  • Mass Spectrometry
  • Microbiology
  • Molecular PCR
  • COVID-19
  • Danaher Corporation
  • Recent Revenue History
    • Table 14-8: Danaher Global IVD Diagnostic Sales, 2017-2023 (million $)
  • Dexcom
  • Recent Revenue History
    • Table 14-9: Dexcom IVD Diagnostic Sales, 2017-2023 (million $)
  • DiaSorin
  • Recent Revenue History
    • Table 14-10: DiaSorin Revenues, 2017-2023 (million $)
  • Immunoassays
  • Molecular
  • COVID-19
  • Exact Sciences
  • Recent Revenue History
    • Table 14-11: Exact Sciences Revenues, 2017-2023 (million $)
  • COVID-19
  • Hologic, Inc.
  • Recent Revenue History
    • Table 14-12: Hologic Revenues, 2017-2023 (million $)
  • PANTHER Molecular System
  • HIV Testing
  • Sexually Transmitted Infections
  • Infectious Diseases
  • Cytology
  • COVID-19
  • Illumina
  • Recent Revenue History
    • Table 14-13: Illumina Diagnostics Revenues, 2017-2023 (million $)
  • COVID-19
  • Instrument Laboratory/ Werfen
  • Expansion
  • Coagulation
  • Acute Care
  • Natera
  • Recent Revenue History
    • Table 14-14: Natera Revenue History 2017-2023 ($ million)
  • Prenatal Paternity Testing
  • QuidelOrtho Corporation
  • Recent Revenue History
    • Table 14-15: QuidelOrtho Revenue History 2018-2023 ($ million)
  • Immunoassays
  • Rapid Immunoassays
  • The Solana Business
  • Molecular - Savanna
  • Blood Bank
  • COVID-19
  • Revvity
    • Table 14-16: Revvity Revenue History 2021-2023 ($ million, estimated)
  • Roche Diagnostics
  • Recent Revenue History
    • Table 14-17: Roche Diagnostics IVD Revenues, 2017-2023 (million $)
  • Hematology
  • Core Lab
  • Immunoassays
  • HIV
  • Core Molecular
  • Digital PCR
  • Diabetes Care
  • Coagulation
  • cobas Liat System - POC
  • HPV
  • Blood Bank
  • Transplant Medicine
  • Cancer Companion Testing
  • COVID-19
  • Siemens Healthineers (Siemens)
  • Recent Revenue History
    • Table 14-18: Siemens Healthineers IVD Revenues, 2017-2023 (million $)
  • Immunoassays
  • Hematology
  • Molecular
  • Acute Care - POC
  • COVID-19
  • Sysmex Corporation
  • Recent Revenue History
    • Table 14-19: Sysmex IVD Revenues 2018-2023 (million $) FY March 31
  • Hematology
  • Coagulation
  • Urinalysis
  • Immunoassays
  • Precision Medicine / Companion Test Diagnostics
  • Oncology
  • COVID-19
  • Thermo Fisher Scientific Inc.
  • Recent Revenue History
    • Table 14-20: Thermo Fischer IVD Revenues, 2017-2023 (million $)
  • Immunoassays
  • Microbiology
  • Next Generation Sequencing
  • Molecular and qPCR
  • Mass Spectrometry
  • COVID-19
  • Werfen
  • Recent Revenue History
    • Table 14-21: Werfen IVD Revenues, 2017-2023 (million $)
  • Hematology and Coagulation
  • Autoimmunity

Contact Us